MDT

86.5

-0.05%↓

113.77

-1.1%↓

VEEV

171.16

-1.2%↓

HQY

81.09

-3.2%↓

PHR.US

9.11

+2.36%↑

MDT

86.5

-0.05%↓

113.77

-1.1%↓

VEEV

171.16

-1.2%↓

HQY

81.09

-3.2%↓

PHR.US

9.11

+2.36%↑

MDT

86.5

-0.05%↓

113.77

-1.1%↓

VEEV

171.16

-1.2%↓

HQY

81.09

-3.2%↓

PHR.US

9.11

+2.36%↑

MDT

86.5

-0.05%↓

113.77

-1.1%↓

VEEV

171.16

-1.2%↓

HQY

81.09

-3.2%↓

PHR.US

9.11

+2.36%↑

MDT

86.5

-0.05%↓

113.77

-1.1%↓

VEEV

171.16

-1.2%↓

HQY

81.09

-3.2%↓

PHR.US

9.11

+2.36%↑

Home・Aandelen Lijst・VolitionRX Ltd

VolitionRX Ltd

Open

0.16 -5.88

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

0.14

Max

0.17

Belangrijke statistieken
By Trading Economics
Inkomsten	936K -5.4M
Verkoop	221K 627K
Winstmarge	-857.414
Werknemers	75
EBITDA	1.3M -4.2M

Aanbevelingen
By TipRanks
Aanbevelingen	Buy
12 Maanden Prognose	+1076.47% upside

Dividenden
By Dow Jones
Volgende Winsten	14 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	-21M 26M
Vorige openingsprijs	6.04
Vorige sluitingsprijs	0.16

VolitionRX Ltd Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

6 apr 2026, 23:17 UTC

Winsten

Samsung Forecasts Record First-Quarter Operating Profit

6 apr 2026, 23:00 UTC

Populaire aandelen

Stocks to Watch: Health Insurers, Mawson, Owlet

6 apr 2026, 22:13 UTC

Belangrijke Marktbewegers

Health Insurance Shares Gain on 2.48% Medicare Rate Bump

6 apr 2026, 21:46 UTC

Acquisities, Fusies, Overnames

BP 'Optimizes Portfolio' and Sells 13 Thorntons Stores to Giant Oil -- OPIS

6 apr 2026, 17:09 UTC

Belangrijke Marktbewegers

Viridian Shares Fall After Competing Amgen Eye Drug Performs Well

6 apr 2026, 16:56 UTC

Belangrijke Nieuwsgebeurtenissen

U.S. Released 1.5 Million Bbls of Crude From SPR Last Week, DOE Data Show -- OPIS

6 apr 2026, 14:47 UTC

Belangrijke Marktbewegers

Stereotaxis Shares Rise on FDA Clearance for Synchrony

7 apr 2026, 00:00 UTC

Belangrijke Nieuwsgebeurtenissen

Ukraine's Lesson for Trump: Military Dominance Opens Waterways -- WSJ

6 apr 2026, 23:58 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Iran War Will Keep Oil Prices High Through 2Q, Says Westpac -- Market Talk

6 apr 2026, 23:50 UTC

Marktinformatie

Nikkei May Rise on Hopes for Iran Cease-Fire -- Market Talk

6 apr 2026, 23:36 UTC

Marktinformatie

Gold Edges Higher as Investors Focus on U.S.-Iran Conflict -- Market Talk

6 apr 2026, 23:15 UTC

Marktinformatie

RBA Won't Raise Rates as Australia's Economy Softens Fast -- Market Talk

6 apr 2026, 22:52 UTC

Marktinformatie

Global Equities Roundup: Market Talk

6 apr 2026, 22:52 UTC

Marktinformatie

Pro Medicus Unlikely to Complete New Buyback in Full -- Market Talk

6 apr 2026, 22:14 UTC

Marktinformatie

Correction to Live Cattle Futures Article

6 apr 2026, 20:56 UTC

Marktinformatie

Mexican Private Consumption Fell in January -- Market Talk

6 apr 2026, 20:50 UTC

Marktinformatie

Energy & Utilities Roundup: Market Talk

6 apr 2026, 20:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

6 apr 2026, 19:58 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

6 apr 2026, 19:58 UTC

Marktinformatie

Live Cattle Futures Hit Record High, Hogs Edge Up -- Market Talk

6 apr 2026, 19:11 UTC

Marktinformatie

U.S. Natural Gas Edges Up in Rangebound Trade -- Market Talk

6 apr 2026, 19:06 UTC

Marktinformatie

Treasury Yields Decline as a Belligerent Trump Talks to Reporters -- Market Talk

6 apr 2026, 19:03 UTC

Marktinformatie

Global Energy Roundup: Market Talk

6 apr 2026, 19:03 UTC

Marktinformatie

Crude Futures Edge Up As Trump's Iran Deadline Nears -- Market Talk

6 apr 2026, 18:36 UTC

Acquisities, Fusies, Overnames

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 apr 2026, 17:59 UTC

Marktinformatie

Belangrijke Nieuwsgebeurtenissen

Travel Booking Companies Facing More Demand Uncertainty Than Expected -- Market Talk

6 apr 2026, 17:13 UTC

Acquisities, Fusies, Overnames

Soleno Stock Soars 32% on $2.9 Billion Neurocrine Buyout. Why Its Hunger Drug Is a Different Weight-Loss Play. -- Barrons.com

6 apr 2026, 16:33 UTC

Marktinformatie

Oil Futures Steady as Market Awaits Trump -- Market Talk

6 apr 2026, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

6 apr 2026, 14:59 UTC

Winsten

Strategy Records a $14.5 Billion Unrealized Loss in First Quarter -- WSJ

Peer Vergelijking

Prijswijziging

VolitionRX Ltd Prognose

Koersdoel

By TipRanks

1076.47% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 2 USD 1076.47%

Hoogste 3 USD

Laagste 1 USD

Gebaseerd op 2 Wall Street-analisten die 12-maands prijsdoelen bieden voor VolitionRX Ltd - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

2 ratings

Buy

Hold

Sell

Gebaseerd op 2 analisten die aandelenratings hebben gegeven aan VolitionRX Ltd - Dist in de afgelopen 3 maanden.

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over VolitionRX Ltd

VolitionRx Limited, a multi-national epigenetics company, engages in the development of blood tests to help diagnose and monitor a range of cancers, and sepsis and COVID-19 in the United States and internationally. The company offers Nu.Q Vet, a cancer screening test for dogs and other animals; Nu.Q Nets for monitoring the immune system; Nu.Q Cancer for monitoring disease progression, response to treatment and minimal residual disease; Capture-PCR, an isolating and capturing circulating tumor derived DNA from plasma samples for early cancer detection; and Nu.Q Discover, a solution to profiling nucleosomes. VolitionRx Limited is based in Henderson, Nevada.